Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Biomarker; Therapeutic Use
- 29 Oct 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016.
- 29 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2014 New trial record